Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone- sensitive cancer: A randomized, placebo-controlled trial

Cancer

Volumn 82, Issue 3, 1998, Pages 553-560

  Simons, Jean Paul F H A ^a   Schols, Annemie M W J ^a   Hoefnagels, Janine M J ^b   Westerterp, Klaas R ^c   Ten Velde, Guul P M ^a   Wouters, Emiel F M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Body composition; Cachexia; Cancer; Food intake; Medroxyprogesterone acetate; Resting energy expenditure; Therapy

Indexed keywords

CORTICOSTEROID; CYPROHEPTADINE; HYDRAZINE SULFATE; MEDROXYPROGESTERONE ACETATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY COMPOSITION; CACHEXIA; CALORIC INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENERGY EXPENDITURE; FEMALE; FOOD INTAKE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; APPETITE; BODY COMPOSITION; CACHEXIA; DOUBLE-BLIND METHOD; EATING; ENERGY METABOLISM; FEMALE; HUMANS; MALE; MEDROXYPROGESTERONE 17-ACETATE; NEOPLASMS; PROGESTERONE CONGENERS; WEIGHT LOSS;

EID: 0032006170     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980201)82:3<553::AID-CNCR18>3.0.CO;2-0     Document Type: Article

References (46)

1. Theologides A. Cancer cachexia. Cancer 1979;43(suppl 5):2004-12.
2. Tisdale MJ. Cancer cachexia. Anticancer Drugs 1993;4:115-25.
3. Nelson KA, Walsh D, Sheehan FA. The cancer anorexiacachexia syndrome. J Clin Oncol 1994;12:213-25.
4. Staal-van den Brekel AJ, Schols AM, ten Velde CP, Buurman WA, Wouters EF. Analysis of the energy balance in lung cancer patients. Cancer Res 1994;54:6430-3.
5. Warren S. The immediate causes of death in cancer. Am J Med Sci 1932;184:610-5.
6. DeWys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491-7.
7. Costa C, Bewley P, Aragon M, Siebold J. Anorexia and weight loss in cancer patients. Cancer Treat Rep 1981;65(suppl 5):3-7.
8. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607-9.
9. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985;69:751-4.
10. Kardinal CG, Loprinzi CL, Schaid DJ, Hass AC, Dose AM, Athmann LM, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657-62.
11. Chlebowski RT, Bulcavage L, Grosvenor M, Oktay E, Block JB, Chlebowski JS, et al. Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J Clin Oncol 1990;8:9-15.
12. Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, Schäfer P, et al. Randomized trial of low-versus-high-dose medroxyprogesterone acetate in the treatment of postmenopausal patients with advanced breast cancer. In: Pellegrini A, Robustelli Della Cuna G, editors. Role of medroxyprogesterone in endocrine-related tumors. vol. 3. New York: Raven Press, 1984:79-89.
13. Tchekmedyian NS, Tait N, Moody M, Aisner J. High-dose megestrol acetate: a possible treatment for cachexia. JAMA 1987;257:1195-8.
14. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990;66:1279-82.
15. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-32.
16. Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, et al. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992;69:1268-74.
17. Feliu J, Gonzalez-Baron M, Berrocal A, Artal A, Ordonez A, Garrido P, et al. Usefulness of megestrol acetate in cancer cachexia and anorexia. Am J Clin Oncol 1992;15:436-40.
18. Rowland KM Jr., Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol/placebo in extensive-stage small-cell lung cancer: a north central cancer treatment group study. J Clin Oncol 1996;14:135-41.
19. Simons JP, Aaronson NK, Vansteenkiste JF, ten Velde GP, Muller MJ, Drenth BM, et al. The effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol 1996;14:1077-84.
20. Tchekmedyian NS, Tait N, Abrams J, Aisner J. High-dose megestrol acetate in the treatment of advanced breast cancer. Semin Oncol 1988;15(suppl 1):44-9.
21. Block G. A review of validations of dietary assessment methods. Am J Epidemiol 1982;115:492-505.
22. NEVO table. Stichting Nederlands voedingsstoffenbestand's gravenhage. The Netherlands: Voorlichtingsbureau voor de Voeding, 1990.
23. 2H labeled water. Am J Clin Nutr 1980; 33:2686-93.
24. van der Kooy K, Leenen R, Deurenberg P, Seidell JC, Westerterp KR, Hautvast JG. Changes in fat-free mass in obese subjects after weight loss: a comparison of body composition measures. Int J Obes Relat Metab Disord 1992;16:675-83.
25. Barrie A, Coward WA. A rapid analytical technique for the determination of energy expenditure by the doubly labelled water method. Biomed Mass Spectrom 1985;12:535-41.
26. Westerterp KR, Wouters L, van Marken Lichtenbelt WD. The Maastricht protocol for the measurement of body composition and energy expenditure with labeled water. Obes Res 1995;3(1 suppl):49-57.
27. Forbes GB. Techniques for estimating body composition. In: Forbes GB, editor. Human body composition. New York: Springer-Verlag, 1987:5-100.
28. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949; 109:1-9.
29. Schols AM, Schoffelen PF, Ceulemans H, Wouters EF, Saris WH. Measurement of resting energy expenditure in patients with chronic obstructive pulmonary disease in a clinical setting. JPEN 1992;16:364-8.
30. Jennrich RI, Schluchter MD. Unbalance repeated-measures models with structured covariance matrices. Biometrics 1986;42:805-20.
31. Dixon WJ, chief editor. BMDP statistical software, to accompany the 7.0 software release. Berkeley: University of California Press, 1992.
32. Metropolitan Life Insurance Company. New weight standards for men and women. Stat Bull Metrop Life Found 1983;64:1-4.
33. Löwik MR, Westenbrink S, Meulmeester JF, van de Berg H, Hulshof KF, Kistemaker C, et al. Onderzoek naar de voeding en voedingstoestand van zelfstandig wonende mensen van 65 tot 80 jaar. Voeding 1987;48:177-91.
34. Fearon KC, Preston T. Body composition in cancer cachexia. Infusionstherapie 1990;17(suppl 3):63-6.
35. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152-4.
36. Oster MH, Enders SR, Samuels SJ, Cone, LA, Hooton TM, Browder HP, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994;121:400-8.
37. Von Roenn JH, Armstrong D, Kotler DP, Cohn DL, Klimas NG, Tchekmedyian NS, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994;121:393-9.
38. Willemse PH, van der Ploeg E, Sleijfer DT, Tjabbes T, van Veelen H. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 1990;26:337-43.
39. Engelson ES, Pi-Sunyer FX, Kotler DP. Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS [letter]. AIDS 1995;9:1107-8.
40. Visser M, de Groot LC, Deurenberg P, van Staveren WA. Validation of dietary history method in a group of elderly women using measurements of total energy expenditure. Br J Nutr 1995;74:775-85.
41. Sawaya AL, Tucker K, Tsay R, Willett W, Saltzman E, Dallal GE, et al. Evaluation of four methods for determining energy intake in young and older women: comparison with doubly labelled water measurements of total energy expenditure. Am J Clin Nutr 1996;63:491-9.
42. Dewys WD. Anorexia as a general effect of cancer. Cancer 1979;43(suppl 5):2013-9.
43. Rohner-Jeanrenaud F. A neuroendocrine reappraisal of the dual-centre hypothesis: its implications for obesity and insulin resistance. Int J Obes Relat Metab Disord 1995;19:517-34.
44. McCarthy HD, Crowder RE, Dryden S, Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994;265:99-102.
45. Dryden S, Frankish H, Wang Q, Williams G. Neuropeptide Y and energy balance: one way ahead for the treatment of obesity? Eur J Clin Invest 1994;24:293-308
46. Hamburger AW, Parnes H, Gordon GB, Shantz LM, O'Donnell KA, Aisner J. Megestrol acetate-induced differentation of 3T3-L1 adipocytes in vitro. Semin Oncol 1988;15(suppl 1):76-8.